Molecular genetics of head and neck cancer

Cancer Control

Volumn 9, Issue 5, 2002, Pages 369-378

  Gleich, Lyon L ^a,b   Salamone, Frank N ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; GENE THERAPY; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR GENETICS; ONCOGENE; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0036750327     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900502     Document Type: Article

References (107)

1. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15-16.
2. Jenkins JR, Rudge K, Chumakov P, et al. The cellular oncogene p53 can be activated by mutagenesis. Nature. 1985;317:816-818.
3. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res. 1999;5:2810-2819.
4. Bradford CR, Zhu S,Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg. 1995;113:408-412.
5. Hirvikoski P, Kumpulainen E, Virtaniemi J, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol. 1997;15:3111-3120.
6. Kapranos N, Stathopoulos GP, Manolopoulos L, et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 2001;21:521-528.
7. Kaur J, Srivastava A, Ralhan R. Prognostic significance of p53 protein overexpression in betel-and tobacco-related oral oncogenesis. Int J Cancer. 1998;79:370-375.
8. Kokoska MS, Piccirillo JF, el-Mofty SK, et al. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer. 1996;78:1693-1700.
9. Mao C, Lu Y, Lai Q, et al. Expression of p53 gene in oral squamous cell carcinoma and its relation with clinical and pathological parameters and prognosis of patients. Chin Med Sci J. 1995;10:199-203.
10. Michalides RJ, van Veelen NM, Kristel PM, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997;123:497-502.
11. Narayana A, Vaughan AT, Kathuria S, et al. P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiat Oncol Biol Phys. 2000;46:21-26.
12. Osaki T, Kimura T, Tatemoto Y, et al. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology. 2000;59:36-43.
13. Portugal LG, Goldenberg JD, Wenig BL, et al. Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1997;123:1230-1234.
14. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer. 1998;79:263-268.
15. Raybaud-Diogene H, Fortin A, Morency R, et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol. 1997;15:1030-1038.
16. Wilson GD, Richman PI, Dische S, et al. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer. 1995;71:1248-1252.
17. Gleich LL, Li YO, Biddinger PW, et al. The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope. 1996;106:1378-1381.
18. Bradford CR, Zhu S, Poore J, et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg. 1997;123:605-609.
19. Chomchai J, Du W, Sarkar F, et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope. 1999;109:455-459.
20. Hegde PU, Brenski AC, Caldarelli DD, et al. Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124:80-85.
21. Hiranuma H, Jikko A, Maeda T, et al. An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. Oral Oncol. 1998;34:513-518.
22. Hogmo A, Borresen-Dale AL, Blegen H, et al. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas. Anticancer Res. 1999;19:3433-3438.
23. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1580-1586.
24. Ostwald C, Gogacz P, Hillmann T, et al. p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer. 2000;88:82-86.
25. Saunders ME, MacKenzie R, Shipman R, et al. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. Clin Cancer Res. 1999;5:2455-2463.
26. Shima K, Kobayashi I, Saito I, et al. Incidence of human papillomavirus 16 and 18 infection and p53 mutation in patients with oral squamous cell carcinoma in Japan. Br J Oral Maxillofac Surg. 2000;38:445-450.
27. Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell. 1989;58:1097-1105.
28. Dokiya F, Ueno K, Ma S, et al. Retinoblastoma protein expression and prognosis in laryngeal cancer. Acta Otolaryngol. 1998;118:759-762.
29. El-Naggar AK, Lai S, Clayman GL, et al. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol. 1999;30:1013-1018.
30. Ioachim E, Assimakopoulos D, Agnantis NJ, et al. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: an immunohistochemical study including correlation with p53, bcl-2 and proliferating indices. Anticancer Res. 1999;19:541-545.
31. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, et al. Alterations of p53, pRb, cydin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 2000;36:334-339.
32. Nakahara Y, Shintani S, Mihara M, et al. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett. 2000;160:3-8.
33. Pande P, Mathur M, Shukla N, et al. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol. 1998;34:396-403.
34. Pavelic ZP, Lasmar M, Pavelic L, et al. Absence of retinoblastoma gene product in human primary oral cavity carcinomas. Eur J Cancer B Oral Oncol. 1996;32B:347-351.
35. Regezi JA, Dekker NP, McMillan A, et al. p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. Oral Oncol. 1999;35:379-383.
36. Xu J, Gimenez-Conti IB, Cunningham JE, et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer. 1998;83:204-212.
37. Scholnick SB, Sun PC, Shaw ME, et al. Frequent loss of heterozygosity for Rb,TP53, and chromosome arm 3p, but not NME1 in squamous cell carcinomas of the supraglottic larynx. Cancer. 1994;73:2472-2480.
38. Yokoyama J, Shiga K, Sasano H, et al. Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers. Anticancer Res. 1996;16:641-644.
39. Sartor M, Steingrimsdottir H, Elamin F, et al. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Br J Cancer. 1999;80:79-86.
40. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503-506.
41. Rasmussen UB, Wolf C, Mattei MG, et al. Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res. 1993;53:4096-4101.
42. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
43. Jares P, Fernandez PL, Nadal A, et al. p16MTS1/CDK41 mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene. 1997;15:1445-1453.
44. Danahey DG, Tobin EJ, Schuller DE, et al. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol. 1999;119:285-288.
45. Matsuda H, Konishi N, Hiasa Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med. 1996;25:232-238.
46. Olshan AF, Weissler MC, Pei H, et al. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene. 1997;14:811-818.
47. Shintani S, Nakahara Y, Mihara M, et al. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol. 2001;37:498-504.
48. Sanchez-Cespedes M, Esteller M,Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;60:892-895.
49. Rosas SL, Koch W, Carvalho MG, et al. Promoter hypermethylation patterns of p16, 06-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61:939-942.
50. Agarwal S, Mathur M, Shukla NK, et al. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. Oral Oncol. 1998;34:353-360.
51. Erber R, Klein W, Andl T, et al. Aberrant p21(ClP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer. 1997;74:383-389.
52. Hirvikoski P, Kellokoski JK, Kumpulainen EJ, et al. Downregulation of p21/WAF1 is related to advanced and dedifferentiated laryngeal squamous cell carcinoma. J Clin Pathol. 1999;52:440-444.
53. Jeannon JP, Soames J, Lunec J, et al. Expression of cyclindependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. Clin Otolaryngol. 2000;25:23-27.
54. Kuo MY, Chang HH, Hahn LJ, et al. Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med. 1995;24:255-260.
55. Mineta H, Miura K, Suzuki I, et al. p27 expression correlates with prognosis in patients with hypopharyngeal cancer. Anticancer Res. 1999;19:4407-4412.
56. Ng IO, Lam KY, Ng M, et al. Expression of p21/waf1 in oral squamous cell carcinomas: correlation with p53 and mdm2 and cellular proliferation index. Oral Oncol. 1999;35:63-69.
57. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol. 1999;17:3150-3315
58. Ralhan R, Agarwal S, Mathur M, et al. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer Res. 2000;6:2440-2447.
59. Tatemoto Y, Osaki T, Yoneda K, et al. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. Pathol Res Pract. 1998;194:821-830.
60. van Oijen MG, Tilanus MG, Medema RH, et al. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med. 1998;27:367-375.
61. Yook JI, Kim J. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol. 1998;34:198-203.
62. Yuen PW, Chow V, Choy J, et al. The clinicopathologic significance of p53 and p21 expression in the surgical management of lingual squamous cell carcinoma. Am J Clin Pathol. 2001;116:240-245.
63. Kudo Y, Takata T, Ogawa I, et al. Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett. 2000;151:217-222.
64. Tamura N, Dong Y, Sui L, et al. Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas. J Laryngol Otol. 2001;115:400-406.
65. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
66. Okami K, Reed AL, Cairns P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene. 1999;18:3541-3545.
67. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997;79:380-389.
68. Capaccio P, Carboni N, Pignataro L, et al. Cyclin D1, p53, mdm2, and Ki67 protein expression in preneoplastic lesions of the larynx. J Chemother. 1997;9:113-114.
69. Kyomoto R, Kumazawa H,Toda Y, et al. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein overexpression in human head-and-neck squamous-cell carcinoma. Int J Cancer. 1997;74:576-581.
70. Masuda M, Hirakawa N, Nakashima T, et al. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer. 1996;78:390-395.
71. Pignataro L, Pruneri G, Carboni N, et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol. 1998;16:3069-3077.
72. Bellacosa A, Almadori G, Cavallo S, et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res. 1996;2:175-180.
73. Callender T, El-Naggar AK, Lee MS, et al. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994;74:152-158.
74. Fortin A, Guerry M, Guerry R, et al. Chromosome 11q13 gene amplifications in oral and oropharyngeal carcinomas: no correlation with subclinical lymph node invasion and disease recurrence. Clin Cancer Res. 1997;3:1609-1614.
75. Gleich LL, Li YQ, Wang X, et al. Variable genetic alterations and survival in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1999;125:949-952.
76. Meredith SD, Levine PA, Bums JA, et al. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995;121:790-794.
77. Muller D, Millon R, Velten M, et al. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer. 1997;33:2203-2210.
78. Derynck R. The physiology of transforming growth factor-alpha. Adv Cancer Res. 1992;58:27-52.
79. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 1991;13:132-139.
80. Krecicki T, Jelen M, Zalesska-Krecicka M, et al. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol. 1999;35:180-186.
81. Wen QH, Miwa T, Yoshizaki T, et al. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope. 1996;106:884-888.
82. Rubin Grandis J, Chakraborty A, Melhem MF, et al. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 1997;15:409-416.
83. Zhong Z, Wen Z, Darnell JE, Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95-98.
84. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000;97:4227-4232.
85. Grandis JR, Zeng Q, Drenning SD. Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope. 2000;110:868-874.
86. Singh B, Gogineni S, Goberdhan A, et al. Spectral karyotyping analysis of head and neck squamous cell carcinoma. Laryngoscope. 2001;111:1545-1550.
87. Bockmuhl U, Wolf G, Schmidt S, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck. 1998;20:145-151.
88. Li X, Lee NK, Ye YW, et al. Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst. 1994;86:1524-1529.
89. Villaret DB, Wang T, Dillon D, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope. 2000;110(3 pt 1):374-381.
90. Cortesina G, Sacchi M, Galeazzi E, et al. Immunology of head and neck cancer: perspectives. Head Neck. 1993;15:74-77.
91. Grandis JR, Falkner DM, Melhem MF, et al. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000;6:2794-2802.
92. Spafford MF, Koch WM, Reed AL, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res. 2001;7:607-612.
93. Gottschlich S, Folz BJ, Goeroegh T, et al. A new prognostic indicator for head and neck cancer - p53 serum antibodies? Anticancer Res. 1999;19:2703-2705.
94. Ralhan R, Nath N, Agarwal S, et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res. 1998;4:2147-2152.
95. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:429-435.
96. Nathan CA, Sanders K, Abreo FW, et al. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res. 2000;60:3599-3604.
97. Clayman GL, El-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:2221-2232.
98. Kirn D, Hermiston T, McCormick E ONYX-015: clinical data are encouraging. Nat Med. 1998;4:1341-1342.
99. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
100. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289-298.
101. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
102. Gleich LL. Gene therapy for head and neck cancer. Laryngoscope. 2000;110:708-726.
103. Gleich LL, Gluckman JL, Nemunaitis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001;127:775-779.
104. Rocco JW, Li D, Liggett WH, Jr, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res. 1998;4:1697-1704.
105. Clayman GL, Liu TJ, Overholt SM, et al. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch Otolaryngol Head Neck Surg. 1996;122:489-493.
106. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
107. Shin DM, Charuruks N, Lippman SM, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001;10:603-609.